LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Accueil・Liste d'Actions・Lantheus Holdings Inc

Lantheus Holdings Inc

Fermé

SecteurSoins de santé

100.73 6.83

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

94.18

Max

101

Chiffres clés
By Trading Economics
Revenu	64M 118M
Ventes	-29M 377M
P/E Moyenne du Secteur	22.127 49.701
BPA	1.46
Marge bénéficiaire	31.383
Employés	1,193
EBITDA	-17M 81M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+0.24% upside

Dividendes
By Dow Jones
Prochains Résultats	5 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	321M 6B
Ouverture précédente	93.9
Clôture précédente	100.73

Sentiment de l'Actualité

By Acuity

49%

51%

157 / 345 Classement par Healthcare

Lantheus Holdings Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

25 mai 2026, 08:24 UTC

Principaux Mouvements du Marché

Acquisitions, Fusions, Rachats

Uber's $11.6 Billion Takeover Approach Lifts Delivery Hero Shares

25 mai 2026, 21:22 UTC

Résultats

Disney's 'Mandalorian and Grogu' Conquers Memorial Day Weekend Box Office -- Barrons.com

25 mai 2026, 20:50 UTC

Market Talk

Résultats

Basic Materials Roundup: Market Talk

25 mai 2026, 16:20 UTC

Market Talk

Résultats

Basic Materials Roundup: Market Talk

25 mai 2026, 16:01 UTC

Market Talk

China's Crude Imports Pullback Helps Cap Price Upside -- Market Talk

25 mai 2026, 14:43 UTC

Market Talk

Oil Unlikely to Fall Significantly Until Hormuz Fully Reopens -- Market Talk

25 mai 2026, 14:15 UTC

Market Talk

Crude Futures Retreat As U.S.-Iran Progress Toward Deal -- Market Talk

25 mai 2026, 13:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

25 mai 2026, 12:58 UTC

Market Talk

Over 60% of Albertans Indicate No Interest in Separation From Canada -- Market Talk

25 mai 2026, 12:56 UTC

Market Talk

Résultats

Canadian Earnings Lifted by Higher Commodity Prices in Latest Quarter -- Market Talk

25 mai 2026, 12:48 UTC

Market Talk

Interest-Rate Cuts Unlikely in 2026 Even if Middle East Conflict Ends -- Market Talk

25 mai 2026, 12:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

25 mai 2026, 12:34 UTC

Market Talk

Dollar Extends Falls on U.S.-Iran Deal Prospects -- Market Talk

25 mai 2026, 12:10 UTC

Market Talk

Acquisitions, Fusions, Rachats

Delivery Hero's Assets Look Strategic -- Market Talk

25 mai 2026, 11:00 UTC

Market Talk

Euro, Sterling, Riskier Currencies Rise Versus Weaker Dollar -- Market Talk

25 mai 2026, 10:19 UTC

Market Talk

Swiss Franc Rises to Highest in More Than Two Months Vs Euro -- Market Talk

25 mai 2026, 10:05 UTC

Résultats

Tenaga Nasional: Well-Positioned to Navigate Global Geopolitical Uncertainties

25 mai 2026, 10:04 UTC

Résultats

Tenaga Nasional: Operational Performance to Remain Resilient in 2026

25 mai 2026, 10:03 UTC

Résultats

Tenaga Nasional: 1Q Operating Profit Rose on Higher Electricity Demand, Lower Fuel Prices

25 mai 2026, 10:02 UTC

Résultats

Tenaga Nasional: 1Q Rev Rose on Higher Electricity Sales

25 mai 2026, 10:01 UTC

Résultats

Tenaga Nasional 1Q Net Up 3.7% on Year

25 mai 2026, 10:00 UTC

Résultats

Tenaga Nasional 1Q Rev Up 6.6% on Year

25 mai 2026, 09:56 UTC

Résultats

Tenaga Nasional Malaysia 1st-Quarter 2026 Earnings Summary Table

25 mai 2026, 09:56 UTC

Résultats

Tenaga Nasional 1Q EPS MYR0.1883

25 mai 2026, 09:56 UTC

Résultats

Tenaga Nasional 1Q Rev MYR17.1B

25 mai 2026, 09:56 UTC

Résultats

Tenaga Nasional 1Q Net MYR1.1B

25 mai 2026, 09:38 UTC

Market Talk

U.S.-Iran Talks Lifted Sentiment But No Agreement Would Quickly Restore Normal Market Conditions -- Market Talk

25 mai 2026, 09:33 UTC

Market Talk

Global Equities Roundup: Market Talk

25 mai 2026, 09:33 UTC

Market Talk

India's Gold Import Tax Raise Won't Curb Demand -- Market Talk

25 mai 2026, 08:55 UTC

Market Talk

European Energy Stocks Slide on Falling Oil Prices -- Market Talk

Comparaison

Variation de prix

Lantheus Holdings Inc prévision

Objectif de Prix

By TipRanks

0.24% hausse

Prévisions sur 12 Mois

Moyen 103.25 USD 0.24%

Haut 115 USD

Bas 90 USD

Basé sur 9 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

9 ratings

Achat

Maintien

Vente

Basé sur 9 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

157 / 345Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Lantheus Holdings Inc

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.